|Dr. Colin Broom||CEO, Interim Chief Medical Officer & Director||658.64k||N/A||1956|
|Mr. Gary L. Sender||Chief Financial Officer||N/A||N/A||1962|
|Mr. Steven P. Gelone Pharm. D||Chief Scientific Officer||N/A||N/A||1968|
|Mr. Thomas Lembck||Chief Information Officer||N/A||N/A||N/A|
|Mr. David Garrett||Head of Investor Relations, VP & Corp. Controller||N/A||N/A||N/A|
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.